ArticleBiomedicines2022

High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy.

Ji-Youn Sung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.